Widespread publicity has been given to the possibility that cimetidine treatment might cause gastric cancer. Preliminary data are given from a post-marketing surveillance study in four centres. A total of 9940 patients taking the drug entered the study and 9504 were observed for at least a year. Seventy-four cases of gastric cancer were identified in those taking cimetidine, but 23 of these were diagnosed before the use of the drug and 29 others with advanced malignancy had received cimetidine within the previous six months only. Ten of the remaining 22 had gastric cancer diagnosed within a year of starting treatment, and 12 after more than a year; only four of the total group had histologically "early" cancer. The occurrence of gastric cancer a long time after starting cimetidine treatment cannot be explained in every case, but it is noteworthy that in a control group (which is not directly comparable) gastric cancer was observed in eight patients.
Introduction
In 1978 we began a post-marketing surveillance study to detect possible adverse effects of cimetidine treatment. We collected information in four centres (Glasgow, Nottingham, Oxford, and Portsmouth) over a period of at least 12 months on patients who had been prescribed cimetidine and on a control group. Details of the methods used in the investigation have been outlined elsewhere. 1 
Subjects and methods
Each patient given a prescription for cimetidine by a general practitioner collaborating in the study was identified through the Prescription Pricing Bureau (Nottingham) or through the local pharmacist who dispensed the prescription (Glasgow, Oxford, Portsmouth). After the patient had been identified, an initial visit to the doctor's practice was made and details of age, sex, and indication for the treatment were recorded. At the same visit a control was recruited for each patient taking cimetidine by selecting the next patient in the practice file of the same sex, whose age was in the same patients' notes were examined, and events requiring outpatient or inpatient consultant advice were recorded for both the taker and the control together with details of deaths and adverse reactions noted by the general practitioner. The recording of prescription information was as far as possible continuous, thus providing a reasonable estimate of exposure to cimetidine.
Recently there has been concern about a possible association between cimetidine and gastric cancer. Accordingly, we decided to review the cases of gastric cancer that occurred in our study, though it was obvious that interpretation of the data would present considerable difficulties. Hospital records, necropsy reports, death certificates, and general practitioner records were examined and in most cases the information obtained was comprehensive.
Results
Details were available after not less than one year of follow-up for 9504 recipients of cimetidine and 8994 controls ( diagnosis was made during the study period, and in one more patient the diagnosis was made three days outside the study period: in these four patients the tumour was advanced at the time of diagnosis. In two cases (one diagnosed in the study period and one after) there were multiple metastases that were presumed on clinical grounds to have come from the stomach but no further information was available.
Discussion
The information we present was compiled because of concern that cimetidine treatment may predispose to to have had treatment for a malignant lesion, though it should be noted that initial endoscopic or radiological examinations gave negative results in four and that two of them had early cancer. The findings in the remaining 12, in whom cancer was diagnosed more than 12 months after starting treatment, are the most difficult to assess. Two had early cancer, and three had cancer diagnosed at least three years after initial treatment; previous endoscopic examination had given either equivocal or negative results in all these three. The importance of the negative findings is, however, uncertain, especially in view of recent reports of an accuracy of only 44% by radiology and of 58% by endoscopy for the diagnosis of early gastric cancer. 4 Even with biopsy, another group5 obtained positive histological findings at endoscopy in only four out of nine cases of early gastric cancer. Two of our 12 cases also had a duodenal ulcer, which is generally considered not to be associated with gastric cancer, though the lesions may co-exist.5 6 Although more cases of gastric cancer were seen in the cimetidine group than in the control group, direct comparison between the two groups is misleading because the basis for their initial selection clearly differed-for example, all the treated group were dyspeptics, while few of the controls were. Further differences between the two groups can be seen by comparing the frequency of other complaints. We have noted that those taking cimetidine have tended to have higher rates of hospital consultation and admission for all complaints, digestive and nondigestive, than the controls.' Another (minor) problem arose because of the design of the study. Controls could be selected only after the patients taking cimetidine had been identified and consequently at any single time the total follow-up experience of cimetidine takers is greater than that of the controls, the difference being, on average, about three months. In this report, however, all cases were recorded and then classified according to the timing of the diagnosis of cancer (figure) to minimise this source of non-comparability between the takers and controls.
The means whereby treatment by agents causing intragastric acid neutralisation in general, and cimetidine in particular, could theoretically cause gastric cancer to develop have been discussed elsewhere.'-10 Our data are reassuring to the extent that most of the cases described can be explained if treatment had been given to patients with symptoms of undiagnosed malignancy. In a few cases such a clear explanation is not possible. Since, however, the clinical course of gastric cancer is not fully known, some cases-and perhaps all-could still represent cancer that was slowly progressive but diagnosed late, and some random GARDEN-RUE iS so well known by this name, and the name Herb of Grace, that I shall not need to write any farther description of it, but shall shew you the virtue of it, as follows.
It is an herb of the Sun, and under Leo. It provokes urine and women's courses, being taken either in meat or drink. The seed thereof taken in wine, is an antidote against all dangerous medicines or deadly poisons. The leaves taken either by themselves, or with figs and walnuts, is called Mithridate's counter-poison against the plague, and causes all venomous things to become harmless; being often taken in meat and drink, it abates venery. A decoction thereof with some dried dill leaves and flowers, eases all pains and torments, inwardly to be drank, and outwardly to be applied warm to the place grieved. The same being drank, helps the pains both of the chest and sides, as also coughs and hardness of breathing, the inflammations of the lungs, and the tormenting pains of the sciatica and the joints, being anointed, or laid to the places; as also the shaking fits of agues, to take a draught before the fit comes. Being boiled or infused in oil, it is good to help the wind cholic, the hardness and windiness of the mother, and frees women from the strangling or suffocation thereof, if the share and the parts thereabouts be anointed therewith. It kills and drives forth the worms of the belly, if it be drank after it is boiled in wine to the half, with a little honey; it helps the gout or pains in the joints, hands, feet or knees, applied thereunto; and with figs it helps the dropsy, being bathed therewith: Being bruised and put into the nostrils, it stays the bleeding thereof. It 
